Disease Assessments in Clinical Trials

Welcome to the online course: Disease Assessments in Clinical Trials.

Evaluating the alteration in tumour size is a crucial aspect of assessing the effectiveness of cancer treatments in clinical settings. Both tumour reduction (objective response) and the duration until disease progression occurs are significant endpoints in cancer clinical trials. Join our panel of experts who will guide you through the fundamentals of disease assessment in clinical trials, ensuring you achieve meaningful endpoints from the outset.

This course aims to equip you with the skills and knowledge necessary to strategically plan tumor assessments, ensuring the achievement of meaningful endpoints from the outset.

This course is delivered over Six Modules:

1. Four Principles of Disease Assessment

2. RECIST Disease Assessments

3. iRECIST Disease Assessments

4. Prostate Cancer Working Group3 Disease Assessments

5. Haematology Disease Assessments Lugano

6. International Myeloma Working Group (IMWG) Uniform Response Criteria